REGULATORY

AMED to Fund 29 New Research Projects to Develop COVID-19 Treatments, including 5 Company-Led Projects

June 24, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Agency for Medical Research and Development (AMED) said on June 19 that it will support 29 new research projects aimed at developing treatments for COVID-19 by providing funding for five projects led by companies and 24 by academia.…

To read the full story

Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020

REGULATORY

LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…